🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

14+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 14 of 14 recruiting trials for “Rare malignant epithelial tumor of liver and intrahepatic biliary tract

NARecruitingNCT06990659

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

👨‍⚕️ Christophe AUBE, Pr, University Hospital, Angers📍 14 sites📅 Started Dec 2025View details ↗
Phase 2RecruitingNCT07146646

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

👨‍⚕️ Madison Conces, MD, Case Comprehensive Cancer Center, University Hospitals📍 2 sites📅 Started Dec 2025View details ↗
Phase 2RecruitingNCT06529718

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

👨‍⚕️ Julien Edeline, MD, Centre Eugène Marquis📍 3 sites📅 Started Oct 2025View details ↗
RecruitingNCT07151118

ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer

👨‍⚕️ Hong Jae Chon, Principal Investigator📍 1 site📅 Started Sep 2025View details ↗
RecruitingNCT07142226

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

👨‍⚕️ Hong Jae Chon, MD. PhD, Principal Investigator📍 1 site📅 Started Sep 2025View details ↗
Phase 2RecruitingNCT07135544

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

🏥 Yongjun Chen📍 1 site📅 Started Aug 2025View details ↗
RecruitingNCT06793709

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

🏥 Eisai Co., Ltd.📍 1 site📅 Started Jul 2025View details ↗
Phase 1, PHASE2RecruitingNCT06708663

HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid Tumours

👨‍⚕️ Lin Shen, Peking University Cancer Hospital & Institute📍 1 site📅 Started Jan 2025View details ↗
RecruitingNCT06653127

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance

👨‍⚕️ Ze-yang Ding, M.D., Tongji Hospital📍 1 site📅 Started Nov 2024View details ↗
Phase 2RecruitingNCT06441747

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

🏥 Australasian Gastro-Intestinal Trials Group📍 8 sites📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT04834674

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

🏥 Sichuan Cancer Hospital and Research Institute📍 1 site📅 Started Jul 2024View details ↗
Phase 1, PHASE2RecruitingNCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

🏥 ModeX Therapeutics, An OPKO Health Company📍 6 sites📅 Started Jun 2024View details ↗
Phase 3RecruitingNCT07062263

Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients

👨‍⚕️ Vikas Ostwal, DM, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India 400012📍 6 sites📅 Started Jul 2023View details ↗
Phase 2, PHASE3RecruitingNCT05065957

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

👨‍⚕️ Li-Tzong Chen, Ph.D, National Institute of Cancer Research📍 5 sites📅 Started Mar 2022View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →